Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7818MR)

This product GTTS-WQ7818MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7818MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3668MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ7660MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ4589MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ14378MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ10726MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ14324MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ9668MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ13481MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW